Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company with a stated thematic focus on domestic pharmaceutical and drug manufacturing targets. The SPAC filed a Form 425 communication with the SEC on July 20, 2026, a disclosure type used for written materials related to a proposed business combination, indicating DMAAR is engaged in an active deal process or has announced a merger target in the U.S. pharmaceutical or life sciences space. The company's name reflects a domestic drug production mandate. Sponsor details and IPO vintage were not identified in the current filing record. For full transaction history, sponsor background, and deal-stage tracking on DMAAR, sign up for complete data access at SpacDesk.